American Century Companies Reduces $10M in Ascendis Pharma A/S ($ASND)
Key Points
- American Century Companies changed its Ascendis Pharma A/S ($ASND) stake by 3.2% last quarter, cutting to 1,397,119 shares worth $301.22 million.
- Wall Street's consensus rating on $ASND is Strong Buy and an average price target of $296.75.
- $ASND last traded around $215.60.
American Century Companies trimmed its position in Ascendis Pharma A/S ($ASND) by 3.2% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,397,119 shares of Ascendis Pharma A/S after selling 46,022 shares during the quarter. American Century Companies's holdings in Ascendis Pharma A/S were worth $301.22 million as of its most recent filing.
Ascendis Pharma A/S ($ASND) Stock
Ascendis Pharma A/S Earnings
Analysts Set New Price Targets
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.